Skip to main content
Top
Published in: Journal of Experimental & Clinical Cancer Research 1/2016

Open Access 01-12-2016 | Erratum

Erratum to: Linc00152 promotes proliferation in gastric cancer through the EGFR-dependent pathway

Authors: Jianping Zhou, Xiaofei Zhi, Linjun Wang, Weizhi Wang, Zheng Li, Jie Tang, Jiwei Wang, Qun Zhang, Zekuan Xu

Published in: Journal of Experimental & Clinical Cancer Research | Issue 1/2016

Login to get access

Excerpt

Unfortunately, the original version of this article [1] contained several errors:
  • Table 1 included incorrect EGFR data. The EGFR data shown were obtained from patients with hepatocellular carcinoma rather than gastric cancer as indicated. These data were erroneously included during the drafting of the manuscript. The correct version of Table 1 showing the EGFR data obtained from gastric cancer patients can be found below. In addition, the correct version of Table 1 below does not show the TNM stage data reported in the original Table; as a result, the last sentence in the section “Cytoplasm located Linc00152 was increased in gastric cancer” should read “Here we found significant correlation with tumour size instead of tumour number, differentiation grade or metastasis.”
    Table 1
    Clinical relevance of Linc00152 and EGFR and patients with gastric cancer
     
    Linc00152
     
    EGFR
     
    Feather
    Low
    High
    P value
    Low
    High
    P value
    All cases
    36
    36
     
    36
    36
     
    Age
       
    0.326
       
    0.637
     <60
    11
    15
     
    13
    13
     
     ≥60
    25
    21
     
    23
    23
     
    Gender
       
    0.422
       
    0.061
     Male
    28
    25
     
    23
    30
     
     Female
    8
    11
     
    13
    6
     
    Differentiation grade
       
    0.616
       
    0.616
     Well
    18
    15
     
    15
    18
     
     Moderate
    16
    17
     
    17
    16
     
     Poorly
    2
    4
     
    4
    2
     
    Tumor Size(cm)
       
    0.004
       
    0.016
     ≤5 cm
    20
    8
     
    19
    9
     
     >5 cm
    16
    28
     
    17
    27
     
    Tumor Number
       
    0.772
       
    0.384
     Solitary
    28
    29
     
    30
    27
     
     Multiple
    8
    7
     
    6
    9
     
    Metastasis
       
    0.475
       
    0.812
     Yes
    22
    19
     
    20
    21
     
     No
    14
    17
     
    16
    15
     
  • In Figure 5, panel a was replicated as panel c. The correct Figure 5 can be found below.
  • The acknowledgements were given as “This work was supported by the Foundation for the Talents in Six Kinds of Profession of Jiangsu Province (JSGF2015D2914 to J.Z.); Natural Science Foundation of Jiangsu Province (BK20151136 to J.Z.).” Instead of “This work was supported by the Foundation for the Talents in Six Kinds of Profession of Jiangsu Province (WSW-075 to J.Z.); Natural Science Foundation of Jiangsu Province (BK20151136 to J.Z.); National Natural Science Foundation of China (81272712, 81072031 to Z.X.); the National Natural Science Foundation Project of International Cooperation (NSFC-NIH, 812111519 to Z.X.); the Program for Development of Innovative Research Team in the First Affiliated Hospital of NJMU, the Priority Academic Program Development of Jiangsu Higher Education Institutions (PAPD, JX 10231801 to Z.X.)”.
Literature
1.
go back to reference Zhou J, Zhi X, Wang L, Wang W, Li Z, Tang J, et al. Linc00152 promotes proliferation in gastric cancer through the EGFR-dependent pathway. J Exp Clin Cancer Res. 2015;34:135.PubMedCentralCrossRefPubMed Zhou J, Zhi X, Wang L, Wang W, Li Z, Tang J, et al. Linc00152 promotes proliferation in gastric cancer through the EGFR-dependent pathway. J Exp Clin Cancer Res. 2015;34:135.PubMedCentralCrossRefPubMed
Metadata
Title
Erratum to: Linc00152 promotes proliferation in gastric cancer through the EGFR-dependent pathway
Authors
Jianping Zhou
Xiaofei Zhi
Linjun Wang
Weizhi Wang
Zheng Li
Jie Tang
Jiwei Wang
Qun Zhang
Zekuan Xu
Publication date
01-12-2016
Publisher
BioMed Central
Published in
Journal of Experimental & Clinical Cancer Research / Issue 1/2016
Electronic ISSN: 1756-9966
DOI
https://doi.org/10.1186/s13046-015-0262-2

Other articles of this Issue 1/2016

Journal of Experimental & Clinical Cancer Research 1/2016 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine